Glivec

Glivec is a prescription medication whose active ingredient is imatinib, provided as an oral formulation with strength not specified in the available data. It belongs to the tyrosine kinase inhibitor class and is marketed in the European Union. The drug works by targeting specific enzymes involved in cell growth, making it a targeted therapy for certain cancers. Glivec is administered under medical supervision and follow‑up monitoring.

Glivec (imatinib) is indicated for the treatment of specific hematologic and solid tumors that are driven by abnormal tyrosine‑kinase activity.

- Chronic myeloid leukemia (CML) in chronic, accelerated, or blast phase. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL) when appropriate. - Gastrointestinal stromal tumor (GIST) that is unresectable or metastatic and expresses KIT or PDGFRA mutations. - Certain other KIT‑positive tumors as determined by a physician.

Adverse reactions to Glivec are documented across clinical trials and real‑world use; they range from mild, frequently observed events to rare but potentially life‑threatening conditions.

Common: - Nausea, vomiting, or decreased appetite, often occurring early in therapy. - Diarrhea or constipation, which may require dietary adjustments. - Fatigue, generalized weakness, or muscle cramps that can affect daily activities.

Serious: - Hepatotoxicity presenting as elevated liver enzymes or clinically significant liver injury. - Cardiac dysfunction, including reduced left‑ventricular ejection fraction or overt heart failure. - Hematologic toxicity such as severe neutropenia, thrombocytopenia, or anemia requiring close monitoring.

Before initiating Glivec, clinicians assess several patient‑specific factors to minimize risks and ensure appropriate monitoring.

- Baseline liver function tests and periodic monitoring during treatment. - Cardiac evaluation, especially in patients with pre‑existing heart disease. - Complete blood count before start and regularly to detect cytopenias. - Assessment of pregnancy status; use only if potential benefit justifies potential risk. - Review of concomitant medications that may affect imatinib metabolism. - Monitoring for signs of fluid retention or edema. - Consider dose adjustments in patients with severe renal impairment.

Glivec is metabolized primarily by the CYP3A4 enzyme, so co‑administration with certain drugs can alter its exposure.

Avoid: - Strong CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, which may reduce efficacy. - Potent CYP3A4 inhibitors like ketoconazole, itraconazole, or clarithromycin, which may increase toxicity.

Use with caution: - Antacids or proton‑pump inhibitors that raise gastric pH, potentially affecting absorption. - Concomitant use of other myelosuppressive agents, increasing risk of blood‑cell disorders. - Drugs that prolong the QT interval, as imatinib may have additive cardiac effects. - Warfarin or other anticoagulants, due to possible altered bleeding risk. - Medications that are substrates of CYP3A4, which may have altered plasma levels.